Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models (2021)
Attributed to:
A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/rheumatology/keaa541
PubMed Identifier: 33141217
Publication URI: http://europepmc.org/abstract/MED/33141217
Type: Journal Article/Review
Parent Publication: Rheumatology
Issue: 3
ISSN: 1462-0324